- Language: English
- Published: September 2012
- Region: Israel
Baxter International Medical Device Company Intelligence Report
- ID: 2396904
- January 2013
- Region: Global
- 39 Pages
- Espicom Business Intelligence Ltd
Medical Device Company Intelligence Reports provide a full review of the company's activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures, major purchasing contracts and litigation. Sections are included on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 60 Medical Device Company Intelligence Reports are currently available.
Baxter International Inc develops, manufactures and markets products for the treatment of haemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. The company applies a combination of expertise in medical devices, pharmaceuticals and biotechnology.
Prior to 2011, Baxter operated under three business segments: BioScience, Medication Delivery and Renal. As of 1st January 2011, the company combined its Medication Delivery and Renal businesses into a single global business unit to form the Medical Products business.
Medical Products – manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, prefilled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anaesthetics. The business also provides products and services related to pharmacy compounding, drug formulation and packaging technologies. In addition, the Medical Products business provides products and services to treat end-stage renal disease. The business manufactures solutions and other products for peritoneal dialysis (PD), a home-based therapy, and distributes products for haemodialysis.
BioScience – processes recombinant and plasma-based proteins to treat haemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as biosurgery products; and vaccines. In March 2010, Baxter acquired ApaTech, which provided the company with immediate entry into the emerging bone fusion field.
This profile primarily concentrates on Baxter’s medical device activities.
In December of 2012, Baxter entered into a definitive agreement to acquire privately-held Gambro, for total consideration approximately US$4.0 billion. Gambro is a global medical technology company focused on developing, manufacturing and supplying dialysis products and therapies for patients with acute or chronic kidney disease. The acquisition will give Baxter a comprehensive dialysis product portfolio, complementing its existing home dialysis offerings.
It is believed that the transaction will provide a number of long-term growth opportunities for Baxter worldwide. With a broad and complementary dialysis product portfolio, Baxter can accelerate product sales in established markets such as Europe, where Gambro has an extensive footprint. Baxter can also expand Gambro's reach in high-growth regions of Latin America and Asia-Pacific, where Baxter has steadily grown its peritoneal dialysis business. In addition, Baxter will also build upon its pipeline of investigational home haemodialysis and automated PD systems with the addition of Gambro's monitors, dialysers, devices and dialysis systems.
In January 2012, Baxter rejected an unsolicited mini-tender offer by TRC Capital Corporation to purchase up to two million shares, or approximately 0.35%, of Baxter’s outstanding common stock at a price of US$46.10 per share in cash. The offer price was 4.67% below the US$48.36 closing price of Baxter’s common stock on 15th December 2011, the day prior to the offer.
Baxter has approximately 48,500 employees and conducts business in over 100 countries. In 2011, the company reported revenues of US$13.89 billion, of which approximately 59% were generated outside of the US. Baxter maintains manufacturing and distribution facilities in a number of locations in the US, Europe, Canada, Asia-Pacific and Latin America.
In Business Monitor International’s list of top ten US medical device manufacturers 2006-2011, Baxter was ranked in fourth position, behind Johnson & Johnson, GE and Medtronic. SHOW LESS READ MORE >
This company report provides:
- Key contact information
- Introduction to the company and its current activities
- Summary of its financial performance
- Who are the company’s major competitors?
- Key recent events in an “at a glance” format
- Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available)
- Table providing in-depth five-year financial analysis
- Employee data, including breakdown by company division and geographic location
Investigates the company’s aims and its areas of focus
Core product areas, key brands, product approvals and launches
Research and Development
- How much has been invested in R&D?
- Where is the research based?
- What alliances and agreements does the company have and with whom?
Manufacturing and Distribution
- Identifying the company’s manufacturing locations
- Sales and marketing facilities
- With whom has the company reached agreements and what do they involve?
- Key contracts awarded
Mergers, Acquisitions, Minority Investments and Divestments
Key Corporate Events